论文部分内容阅读
[目的]探讨阿托伐他汀对急性冠脉综合征(ACS)患者血清内皮素(ET)和血管细胞黏附分子-1(VCAM-1)的影响。[方法]分别采用放射免疫法和ELISA法测定76例ACS患者和40例健康对照组的血清ET和VCAM-1水平。同时将ACS患者随机分为阿托伐他汀治疗组(阿托伐他汀10mg/d,n=38)和对照组(常规治疗,n=38),于治疗前后分别测定血清ET和VCAM-1水平,进行治疗前后的比较和组间比较。[结果](1)与健康对照组相比,ACS患者血清ET和VCAM-1水平显著升高,差异有统计学意义(均为P﹤0.01)。(2)治疗后2周与治疗前相比,阿托伐他汀治疗组和对照组的血清ET和VCAM-1水平显著下降;与对照组相比,阿托伐他汀治疗组治疗后血清ET和VCAM-1水平更低,差异有统计学意义(均为P﹤0.01)。[结论]ACS患者血清ET和VCAM-1水平升高与ACS的粥样斑块形成密切相关。阿托伐他汀等他汀类药物可降低ACS患者血清ET和VCAM-1水平,具有一定的抗内皮损伤及抗炎作用。
[Objective] To investigate the effect of atorvastatin on serum endothelin (ET) and vascular cell adhesion molecule-1 (VCAM-1) in patients with acute coronary syndrome (ACS). [Methods] Serum ET and VCAM-1 levels were measured in 76 patients with ACS and 40 healthy controls by radioimmunoassay and ELISA respectively. At the same time, ACS patients were randomly divided into atorvastatin group (atorvastatin 10 mg / d, n = 38) and control group (n = 38). The levels of serum ET and VCAM-1 were measured before and after treatment , Compared before and after treatment and comparison between groups. [Results] (1) The levels of ET and VCAM-1 in patients with ACS were significantly higher than those in healthy controls (P <0.01). (2) The level of serum ET and VCAM-1 in atorvastatin group and control group decreased significantly at 2 weeks after treatment compared with that before treatment. Compared with the control group, atorvastatin treatment group had significantly lower serum ET and VCAM-1 levels were lower, the difference was statistically significant (both P <0.01). [Conclusion] Elevated ET and VCAM-1 levels in patients with ACS are closely related to the formation of atherosclerotic plaques in ACS. Statins such as atorvastatin reduce serum ET and VCAM-1 levels in patients with ACS, and have certain anti-endothelial and anti-inflammatory effects.